Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in… (NCT07035067) | Clinical Trial Compass
TerminatedNot Applicable
Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada
Stopped: Recruitment
Canada24 participantsStarted 2025-07-15
Plain-language summary
Filling the gap in Canadian evidence on the burden of PROC on QoL is essential. It will help better understand the impact of PROC on multiple aspects of the lives of patients and their caregivers and the real-life hurdles faced by PROC patients and their caregivers. The outputs of this study will help better understand the hurdles and challenges they face and the significant unmet medical need.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. ≥18 years old
✓. Patients with PROC who received \>1 prior line of therapy identified through a screening survey. PROC will be defined as recurrence less than 6 months after last platinum chemotherapy (i.e. carboplatin or cisplatin)
✓. Ability to read and understand French or English
✓. Signature of ICF
Exclusion criteria
✕. Patients with PSOC, defined as those who:
✕. Have not progressed within less than 6 months after completion of platinum-based chemotherapy or;
✕. Are still on platinum chemotherapy or;
✕. Receive maintenance therapy.
✕. Patients with platinum-refractory ovarian cancer, defined as not responding or disease progressing during therapy or within three months after the last dose
✕. ≥18 years old
What they're measuring
1
To estimate the quality of life of patient with ovarian cancer
✕. Current caregiver of a patient with PROC (see definition to be used above) who received \>1 prior line of therapy identified through a screening survey.
✕. Ability to read and understand French or English